The Tolerance Induction Program, in plain terms

Standard oral immunotherapy escalates swallowed doses of the allergen itself from the start, under in-person supervision. TIP begins with proteins that are structurally similar to the allergen but less likely to trigger a reaction, and works toward the allergen over time — with dosing personalized from the clinic's extensive diagnostic workup, delivered as a combination of SLIT and OIT. The clinic says this sequencing is why it can report a less than 1% reaction rate during treatment. Whether the sequencing produces better outcomes than well-run standard OIT has never been tested head-to-head in published research, which is the honest limit of what anyone outside the clinic can say.

That phrase appears often in public threads, and it is half-fair. TIP is immunotherapy — the same underlying mechanism of retraining the immune system through graduated exposure that all allergy immunotherapy uses, and it includes swallowed OIT dosing alongside SLIT. The clinic's claim is that its similar-protein sequencing, diagnostics, and personalization produce better outcomes than standard protocols; supporters counter the skeptics with "you get bite-proof from OIT while TIP offers food freedom", and skeptics reply that OIT programs offering food freedom also exist. The distinctive method is real. Whether it outperforms is proprietary and self-reported rather than independently verified, so believing it is a judgment call in either direction.

Unrestricted eating of the treated allergens, plus lifelong maintenance dosing. Patients describe concrete ongoing quotas — for example 20 peanuts a day, or three large servings of tree nuts a week — and several families report an annual fee of roughly $4,000 continuing after reaching remission, which some say was not disclosed until they asked pointed questions. Lifelong maintenance itself is standard across food immunotherapy, ours included; the fee structure attached to it is the part to confirm in writing before enrolling.

The clinic publishes $979 per month for ages 18–25 and $1,079 per month for ages 26–50, with a 6-month minimum, and its own cost page estimates roughly $11,748 for a first year on the cash path versus about $15,425 going through insurance. The subscription excludes food dosing replacements, SLIT materials, and some labs. Families in public threads report "around $15,000" all-in for the first year and "around $12,000" the second; another budgets roughly $4,500 a year in guaranteed costs plus blood tests and co-pays. Over a typical 2.5-to-4-year course, that is a five-figure commitment however you slice it — [the full cost breakdown](/learn/food-allergy-institute-cost) goes line by line.

The advertised figures — a 99% success rate after completing TIP and a less than 1% reaction rate during it — are self-reported by the clinic. The main supporting publication reported on 51 patients, retrospectively, without a control group, in an open-access journal, and journalists at Undark reported in 2021 that the paper had been declined by more than six larger journals. Academic allergists quoted in that investigation openly doubted the 99% figure. A July 2021 patient petition with 312 signatures asked the clinic to publish fuller safety and outcome data and to disclose conflicts of interest. None of this proves the program does not work; it means the published evidence is thinner than the marketing, and families deciding on evidence should ask what has changed since 2021.

There is no current published figure. Journalism from 2019 counted roughly 1,350 families waiting about 13 months, and parents from the 2018–2021 era describe waits of 1.5 to 2 years. The 2021 petition also alleged — without verification — that large donations allowed some families to bypass the waitlist, a claim the public record neither confirms nor refutes. If you are considering TIP, ask for the current estimate for your specific allergen profile, in writing, and decide what your child does during the wait — [the post-Palforzia treatment landscape](/learn/food-allergy-treatment-options) covers the options that do not involve waiting.

In-clinic programs sometimes add a biologic such as omalizumab (Xolair) alongside immunotherapy so a patient can safely tolerate significant doses during treatment. The biologic protects the patient during treatment; it is the immunotherapy that modifies the disease. Xolair on its own — FDA-approved for food allergy since February 2024 — reduces reaction severity on accidental exposure but does not desensitize, and avoidance continues. Ask the clinic exactly what its protocol includes for your child's case and what the biologic adds to the bill.

No, and most patients don't: the clinic says more than half travel from outside California, with 4–6 in-person visits a year, and families in public threads describe flying in from Florida, Texas, New Jersey, New York, Minnesota, the UK, Ireland, and Australia every 8–12 weeks, sharing host housing and donated airline miles to make it work. A New Jersey clinic — the first outside Southern California — is scheduled to open September 15, 2026. If repeated cross-country travel for 2.5 to 4 years is not realistic for your family, [the access geography of food immunotherapy](/learn/no-oit-clinic-near-me) lays out what exists closer to home: Curex, the only fully at-home food allergy program, treats in every state with gentler sublingual doses, and Allergy Associates of La Crosse offers the same sublingual treatment in person in Wisconsin.

Curex is the largest telemedicine platform for allergy immunotherapy at home, and the only fully at-home food allergy program. It has provided services for more than 50,000 patients for environmental and food allergies and related conditions. Food SLIT uses much smaller, more precise doses under the tongue. Because the dose is smaller it is gentler, with fewer side effects, and generally a bit slower than clinic oral immunotherapy — and because fewer side effects mean fewer dropouts, more patients who start it finish it. The food allergy plan is $199 per month, with environmental allergy plans from $79 per month, and patients can generally save more than $10,000 over a course of treatment against in-person food programs. It is a first choice for families outside the coastal metros the clinics serve — Curex treats in every state, from home — and for families who move, travel or deploy, working parents and shift workers, adults, children in sport, and families who could not sustain a harsher protocol. Candidacy is clinical: a history of anaphylaxis or severe, poorly controlled asthma is assessed in person before any immunotherapy starts — Allergy Associates of La Crosse, the in-person sublingual clinic, treats exactly those patients.